Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Plasma cell 1Other 1

Conditions

Neoplasms 14Lung Neoplasms 10Breast Neoplasms 9Colorectal Neoplasms 8Prostatic Neoplasms 7Stomach Neoplasms 3Rectal Neoplasms 3Polycystic Ovary Syndrome 3Neoplasm Metastasis 3Colonic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Smoking Cessation 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic cancer, adult 2Ovarian Neoplasms 2Neoplastic Cells, Circulating 2Motor Activity 2Lymphoma 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia 2Endometrial Neoplasms 2Wilms Tumor 1Venous Thromboembolism 1Vaginal Neoplasms 1Uveal Melanoma 1Uterine Cervical Neoplasms 1Untreated Human Epidermal Growth Factor Receptor-2(HER2)Positive Early Breast Cancer 1Testicular Germ Cell Tumor 1Stroke 1

Interventions

Doxorubicin 17Echocardiography 14Exercise 9Cyclophosphamide 9Trastuzumab 8Dexrazoxane 8Electrocardiography 7Razoxane 6Carvedilol 6Vincristine 4Radiotherapy 4Filgrastim 4Docetaxel 4Methotrexate 3Granulocyte Colony-Stimulating Factor 3Etoposide 3Cisplatin 3Atorvastatin 3salicylhydroxamic acid 2sacubitril and valsartan sodium hydrate drug combination 2empagliflozin 2dapagliflozin 2Tablets 2Social Determinants of Health 2Silymarin 2Prednisone 2Paclitaxel 2Neoadjuvant Therapy 2Magnetic Resonance Spectroscopy 2Leucovorin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cardiotoxicity × Hematologic Tests × Clear all
NCT04827563 2026-03-04

Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib

University of Chicago

Terminated
50 enrolled
OtherPlasma cell

Dyspnea, Multiple Myeloma, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡